Advances in Colorectal Cancer Screening: Access and Cost

Summary

The article discusses advances in colorectal cancer screening . It focuses on a blood test called Shield and advancements in stool tests. The Shield test shows promise but is less effective than colonoscopies or FIT-DNA stool tests. It may help those hesitant about traditional screenings. However, its effectiveness in younger groups and long-term costs remain unclear.

Key Insights

• Emerging Blood Tests: The Shield blood test finds 83% of colorectal cancer cases. Yet it detects only 13% of advanced polyps, with a 10% false-positive rate. It is not yet FDA-approved but could become more available if approved.
• Stool Tests: FIT-DNA tests like Cologuard are more accurate. They detect 92-94% of colorectal cancer cases and 42-43% of advanced polyps, with fewer false positives.
• Colonoscopies: These remain the gold standard, detecting 95% of cases. However, they are invasive and costly.

Background Context

Colorectal cancer is a leading cause of cancer death in the U.S. Effective screening is vital. Colonoscopies are accurate but often avoided due to discomfort and cost. Newer noninvasive tests aim to boost screening rates. The U.S. Preventive Services Task Force recommends regular screening, including stool tests and colonoscopies. Novel markers are being developed for better noninvasive tests.

Implications

Noninvasive tests like Shield could improve screening adherence by simplifying the process. However, if they replace colonoscopies, cancer rates and costs may rise due to their lower effectiveness. Cost-effectiveness and long-term outcomes need more study. This includes comparing frequent screening with less frequent but more thorough colonoscopies.

Also see original coverage of new approaches to colorectal cancer screening.